Craig H Moskowitz

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy
    Craig Moskowitz
    Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer Chemother Pharmacol 49:S9-12. 2002
  2. ncbi request reprint Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation
    Dorothy Pan
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer J 8:371-6. 2002
  3. ncbi request reprint Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999
    Paul A Hamlin
    Medicine Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 130:691-9. 2005
  4. doi request reprint Interim PET-CT in the management of diffuse large B-cell lymphoma
    Craig H Moskowitz
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Hematology Am Soc Hematol Educ Program 2012:397-401. 2012
  5. doi request reprint Diffuse large B cell lymphoma: how can we cure more patients in 2012?
    Craig Moskowitz
    Division of Hematologic Oncology, Lymphoma and Adult BMT Services, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, United States
    Best Pract Res Clin Haematol 25:41-7. 2012
  6. pmc Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
    Craig H Moskowitz
    Lymphoma Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 119:1665-70. 2012
  7. ncbi request reprint Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma
    C H Moskowitz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 4:311-6. 1998
  8. doi request reprint High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging
    Craig H Moskowitz
    Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Br J Haematol 148:890-7. 2010
  9. ncbi request reprint An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma
    Craig H Moskowitz
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Natl Compr Canc Netw 8:347-52. 2010
  10. ncbi request reprint Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma
    C H Moskowitz
    Hematology Service, New York, NY, USA
    Ann Oncol 18:1842-50. 2007

Detail Information

Publications39

  1. ncbi request reprint Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy
    Craig Moskowitz
    Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer Chemother Pharmacol 49:S9-12. 2002
    ..Novel treatment strategies designed to increase their complete response rate would be anticipated to improve their long-term survival...
  2. ncbi request reprint Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation
    Dorothy Pan
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer J 8:371-6. 2002
    ..In these cases, there is limited salvageability with the use of conventional therapy. The purpose of this retrospective analysis was to evaluate single-agent rituximab as treatment for aggressive non-Hodgkin's lymphomas in these cases...
  3. ncbi request reprint Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999
    Paul A Hamlin
    Medicine Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 130:691-9. 2005
    ....
  4. doi request reprint Interim PET-CT in the management of diffuse large B-cell lymphoma
    Craig H Moskowitz
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Hematology Am Soc Hematol Educ Program 2012:397-401. 2012
    ....
  5. doi request reprint Diffuse large B cell lymphoma: how can we cure more patients in 2012?
    Craig Moskowitz
    Division of Hematologic Oncology, Lymphoma and Adult BMT Services, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, United States
    Best Pract Res Clin Haematol 25:41-7. 2012
    ....
  6. pmc Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
    Craig H Moskowitz
    Lymphoma Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 119:1665-70. 2012
    ..6% for patients with a positive scan (P < .001). This prospective study provides evidence that the goal of SLT in patients with Hodgkin lymphoma should be a negative FDG-PET scan before HDT/ASCT...
  7. ncbi request reprint Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma
    C H Moskowitz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 4:311-6. 1998
    ..Alternative approaches, such as ex vivo expansion or the use of other growth factors in addition to G-CSF, may improve mobilization of progenitor cells for PBPC transplantation...
  8. doi request reprint High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging
    Craig H Moskowitz
    Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Br J Haematol 148:890-7. 2010
    ..61. Risk-adapted augmentation of salvage treatment in patients with HL is feasible and improves EFS in poorer-risk patients. Our data suggest that normalisation of FI pre-ASCT predicts outcome, and should be the goal of salvage treatment...
  9. ncbi request reprint An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma
    Craig H Moskowitz
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Natl Compr Canc Netw 8:347-52. 2010
    ....
  10. ncbi request reprint Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma
    C H Moskowitz
    Hematology Service, New York, NY, USA
    Ann Oncol 18:1842-50. 2007
    ..We incorporated a thrombopoietic agent into the ICE chemotherapy program to potentially: decrease platelet associated toxicities, augment stem cell collection and maintain dose intensity...
  11. pmc Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma
    Craig H Moskowitz
    Departments of Medicine, Radiology, Pathology, and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 28:1896-903. 2010
    ..Outside of a clinical trial, we recommend biopsy confirmation of an abnormal interim FDG-PET scan before changing therapy...
  12. ncbi request reprint Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation
    C H Moskowitz
    Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 17:iv37-9. 2006
    ....
  13. ncbi request reprint Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL
    Craig H Moskowitz
    Lymphoma and Hematology Services of the Division of Hematological Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 106:3383-5. 2005
    ..The cell of origin as determined by IHC does not predict outcome in transplantation-eligible patients with relapsed or primary refractory DLBCL...
  14. ncbi request reprint Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease
    Craig H Moskowitz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, PO Box 350, New York, NY 10021, USA
    Br J Haematol 124:645-52. 2004
    ..001). While patients with chemosensitive disease have an excellent outcome with HDT and ASCT, novel approaches are needed to cure HD patients who fail front-line and second-line chemotherapy...
  15. ncbi request reprint Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
    Paul A Hamlin
    Lymphoma and Hematology Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Box 350, 1275 York Ave, New York, NY, 10021
    Blood 102:1989-96. 2003
    ..This powerful prognostic instrument should be used to evaluate new treatment approaches and to compare results of different regimens...
  16. ncbi request reprint Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
    Tarun Kewalramani
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 103:3684-8. 2004
    ..25). RICE appears to induce very high CR rates in patients with relapsed and refractory DLBCL; however, further studies are necessary to determine whether this treatment regimen will improve outcomes after ASCT...
  17. ncbi request reprint R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy
    Jeffrey L Halaas
    Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Leuk Lymphoma 46:541-7. 2005
    ..Whether adding rituximab and increasing dose intensity improves survival over either alone will require randomized studies...
  18. pmc Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma
    Alison J Moskowitz
    Lymphoma Service of the Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 116:4934-7. 2010
    ..055). Studies evaluating novel STs, conditioning regimens, post-ASCT maintenance, or allogeneic stem cell transplantation are warranted for patients who fail to normalize pre-ASCT functional imaging...
  19. doi request reprint Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma
    John Gerecitano
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York 10065, USA
    Clin Cancer Res 17:2493-501. 2011
    ....
  20. pmc Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies
    Owen A O'Connor
    Lymphoid Development and Malignancy Program, Lymphoma Service, Columbia University, Herbert Irving Comprehensive Cancer Center, 1130 St Nicholas Ave, New York, NY 10032, USA
    J Clin Oncol 27:4357-64. 2009
    ..To determine the maximum-tolerated dose (MTD) and efficacy of pralatrexate in patients with lymphoma...
  21. pmc Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
    Alison J Moskowitz
    Medical Oncology Hematology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 8, New York, NY 10065, USA
    Br J Haematol 146:158-63. 2009
    ..Future studies should focus on prospectively evaluating RIT following HDT-ASCT failure in patients with remission duration from HDT-ASCT of >6 months...
  22. pmc Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma
    Alison J Moskowitz
    Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
    J Clin Oncol 31:456-60. 2013
    ..Limited data exist regarding the activity of bendamustine in Hodgkin lymphoma (HL). This phase II study evaluated the efficacy of bendamustine in relapsed and refractory HL...
  23. doi request reprint Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma
    Karyn A Goodman
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 26:5240-7. 2008
    ....
  24. ncbi request reprint Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma
    Tarun Kewalramani
    Hematology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 134:202-7. 2006
    ..The outcome of ASCT for patients with chemosensitive relapsed or primary refractory PTCL is similar to that for patients with DLBCL...
  25. ncbi request reprint Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis
    Lauren E Abrey
    Departments of Neurology and Medicine and the Office of Clinical Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:4151-6. 2003
    ..To assess the safety and efficacy of intensive methotrexate-based chemotherapy followed by high-dose chemotherapy (HDT) with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma (PCNSL)...
  26. doi request reprint Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity
    Bradford S Hoppe
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10165, USA
    J Clin Oncol 26:1858-64. 2008
    ..To analyze outcome, prognostic factors, and toxicities in patients with diffuse large-cell lymphoma (DLCL) who received involved-field radiotherapy (IFRT) before high-dose chemotherapy with autologous stem-cell rescue (ASCR)...
  27. ncbi request reprint Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma
    Owen A O'Connor
    Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10032, USA
    Br J Haematol 139:425-8. 2007
    ..For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL...
  28. doi request reprint High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma
    Daniel O Persky
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Appl Immunohistochem Mol Morphol 18:35-40. 2010
    ..We sought to determine if we could identify such markers, and if our comprehensive second-line program could overcome their significance...
  29. doi request reprint False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma
    Gary A Ulaner
    all authors, Memorial Sloan Kettering Cancer Center and Gary A Ulaner, Craig H Moskowitz, and Andrew D Zelenetz, Weill Cornell Medical College, New York, NY
    J Clin Oncol 32:51-6. 2014
    ..Determine the clinical significance of [(18)F]fluorodeoxyglucose (FDG)-avid lesions in patients with lymphoma treated with stem-cell transplantation...
  30. pmc Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma
    Matthew J Matasar
    Lymphoma and Adult Bone Marrow Transplant Services, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 122:499-506. 2013
    ..Substitution of ofatumumab for rituximab in standard second-line regimens following failure of R-CHOP is a promising approach. This trial was registered at www.clinicaltrials.gov as NCT00823719. ..
  31. pmc Controversies in the treatment of lymphoma with autologous transplantation
    Alison J Moskowitz
    Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncologist 14:921-9. 2009
    ....
  32. doi request reprint Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma
    Carla Casulo
    Department of Medicine, University of Rochester, Rochester, NY, USA
    Leuk Res 37:1178-83. 2013
    ..However, the impact of TAM in relapsed and refractory disease is unknown...
  33. pmc The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma
    Aashiyana F Koreishi
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Appl Immunohistochem Mol Morphol 18:206-11. 2010
    ..0001). Expression of cytotoxic and regulatory T-cells shows prognostic significance in the relapsed/refractory clinical setting of cHL...
  34. doi request reprint A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission
    Neha Mehta
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY Electronic address
    Clin Lymphoma Myeloma Leuk 13:664-70. 2013
    ..Peripheral T-cell lymphomas are aggressive lymphomas that have no standard treatment. Studies suggest that HD-ASCT in the first CR improves outcome. Few data exist regarding allo-HSCT in the first CR...
  35. ncbi request reprint Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma
    Qianxun Xiao
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Appl Immunohistochem Mol Morphol 12:211-5. 2004
    ..Our results demonstrate that there is differential c-REL protein expression in cHL in comparison with NLPHL and suggest that c-REL may play a role in the pathogenesis of classic Hodgkin lymphoma...
  36. ncbi request reprint Mantle cell lymphomas
    Craig H Moskowitz
    Weill Medical College, Cornell University, New York, USA
    Clin Adv Hematol Oncol 3:suppl 6-7. 2005
  37. doi request reprint Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation
    Trudy N Small
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 15:1538-42. 2009
    ..5microg of PT induces an inadequate response. Prospective trials evaluating BOOSTRIX, containing 8microg/dose of PT (approved for adults in December 2008) are warranted in this vulnerable population undergoing transplantation...
  38. pmc Randomized clinical trial of telephone-administered cognitive-behavioral therapy to reduce post-traumatic stress disorder and distress symptoms after hematopoietic stem-cell transplantation
    Katherine N DuHamel
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 28:3754-61. 2010
    ..We report results of a randomized clinical trial that tested the effects of a 10-session, telephone-administered cognitive-behavioral therapy (CBT) intervention on PTSD, depression, and distress symptoms...
  39. doi request reprint CD5 negative, Cyclin D1-positive diffuse large B-cell lymphoma (DLBCL) presenting as ruptured spleen
    Julie Teruya-Feldstein
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Appl Immunohistochem Mol Morphol 17:255-8. 2009
    ..The patient received multiple therapies and ultimately died. This case raises the differential diagnoses of pleomorphic mantle cell lymphoma and other aggressive lymphomas with pleomorphic, anaplastic, and Reed-Sternberg-like cells...